Weitere Erfolge für Tiroler Quantenphysiker tirol.orf.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tirol.orf.at Daily Mail and Mail on Sunday newspapers.
Posted on 394
Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the appointment of Nikola Trbovic, Ph.D., Executive Director and Partner at Pfizer Ventures, as a member of its Board of Directors.
“Nikola’s expertise in R&D and corporate finance will be an asset to Palleon, and we are very pleased to welcome him to the Board. Nikola will replace Bill Burkoth, who we would like to thank for the valuable support and guidance that he has given to Palleon over the years,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “This is an exciting time of growth for the company as our lead program, an enzymatic sialoglycan degrader for T cell exhaustion in cancer, is expected to enter clinical testing later this year. We look forward to working closely with Nikola as we advance our programs to first
LAPS Hosting COVID Vaccine Presentation For Staff Feb. 10
LAPS News:
All LAPS staff are invited to a presentation on “COVID Vaccines and How They Work” starting at 3 p.m., Wednesday, Feb. 10. Dr. Sandy Farmer of Pfizer Pharmaceutical will be the featured speaker.
Staff will be sent the Zoom link prior to the presentation.
Farmer’s presentation will focus on: how immunity works technology foundation for the top COVID vaccines why now for such innovation in vaccines how mRNA vaccines work and why is this such a powerful platform brief background on Phase 3 vaccine clinical trials and how COVID-19 Phase 3 trials compare
Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform
Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda
The companies will support the rollout of a cloud-based platform with the potential to transform the way the biopharma industry communicates and exchanges information with health authorities worldwide.
BURLINGAME, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) Ten of the world s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission.
Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform
Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda
The companies will support the rollout of a cloud-based platform with the potential to transform the way the biopharma industry communicates and exchanges information with health authorities worldwide.
BURLINGAME, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) Ten of the world’s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission.